| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/09/1998 | WO1998029395A1 Process for producing imidazole derivatives |
| 07/09/1998 | WO1998029390A1 Farnesyl transferase inhibitors |
| 07/09/1998 | WO1998029382A1 Selective inhibitors of prostaglandin endoperoxide synthase-2 |
| 07/09/1998 | WO1998029375A1 Brain targeted low molecular weight hydrophobic antioxidant compounds |
| 07/09/1998 | WO1998029344A1 Fine cisplatin powder and process for the production thereof |
| 07/09/1998 | WO1998029141A1 Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
| 07/09/1998 | WO1998029140A1 Processes and compositions for spray drying hydrophobic drugs in organic solvent suspensions of hydrophilic excipients |
| 07/09/1998 | WO1998029136A1 Stabilized tricyclic compound |
| 07/09/1998 | WO1998029135A1 Drugs for ameliorating ophthalmic circulatory disturbance |
| 07/09/1998 | WO1998029134A2 Microporation of tissue for delivery of bioactive agents |
| 07/09/1998 | WO1998029128A1 Biologically active substances, method for obtaining and compositions containing them |
| 07/09/1998 | WO1998029127A1 Method and non-gelling composition for inhibiting post-surgical adhesions |
| 07/09/1998 | WO1998029126A1 Anticoagulant composition |
| 07/09/1998 | WO1998029125A1 Remedies for bladder disorders |
| 07/09/1998 | WO1998029124A1 Oligonucleotide compositions and methods for the modulation of the expression of b7 protein |
| 07/09/1998 | WO1998029123A1 Method of treating prostatic diseases using active vitamin d analogues |
| 07/09/1998 | WO1998029122A1 Use of active ingredients with oestrogenic effect for the prevention and treatment of macular degeneration |
| 07/09/1998 | WO1998029120A1 Treatment of liposarcomas using a combination of thiazolidinediones and retinoid x receptor selective agonists |
| 07/09/1998 | WO1998029119A1 Inhibitors of farnesyl-protein transferase |
| 07/09/1998 | WO1998029117A1 N-linked ureas and carbamates of heterocyclic thioesters |
| 07/09/1998 | WO1998029116A1 N-linked sulfonamides of heterocyclic thioesters |
| 07/09/1998 | WO1998029115A1 Transition-metal nitrosyl compounds as smooth muscle relaxants |
| 07/09/1998 | WO1998029114A1 Tricarboxylic acid-containing oxyalkyl esters and uses thereof |
| 07/09/1998 | WO1998029113A1 Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor |
| 07/09/1998 | WO1998029111A1 Carcinogenesis inhibitors |
| 07/09/1998 | WO1998029110A2 Formulation and method for treating neoplasms by inhalation |
| 07/09/1998 | WO1998029109A1 Methods and compositions for identification of autoantigens |
| 07/09/1998 | WO1998029108A2 Compositions and methods for restoring a normal pattern of imprinting to cells |
| 07/09/1998 | WO1998029107A2 Poly(diallylamine)-based bile acid sequestrants |
| 07/09/1998 | WO1998029105A2 Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations |
| 07/09/1998 | WO1998029104A2 Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis |
| 07/09/1998 | WO1998029103A2 Use of calcium dobesilate for the manufacture of a medicament for the treatment of embryonic retardation |
| 07/09/1998 | WO1998029101A1 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 07/09/1998 | WO1998029098A1 Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
| 07/09/1998 | WO1998029096A1 Aerosolized hydrophobic drug |
| 07/09/1998 | WO1998029095A2 Sustained release cisapride mini-tablet formulation |
| 07/09/1998 | WO1998029090A1 Moistening preparation |
| 07/09/1998 | WO1998029086A1 Reduction of hair growth |
| 07/09/1998 | WO1998029047A1 Spine distraction implant and method |
| 07/09/1998 | WO1998028990A1 A method to prepare food seasoning, food ingredient and food item compositions, seasoning and use thereof |
| 07/09/1998 | WO1998028989A1 Method and compositions for weight control |
| 07/09/1998 | WO1998028980A1 Inhibitors of farnesyl-protein transferase |
| 07/09/1998 | WO1998022099A3 New use of creatine |
| 07/09/1998 | WO1998022098A3 Cpp32 inhibitors for regulating apoptosis |
| 07/09/1998 | WO1998017796A3 Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit |
| 07/09/1998 | WO1998008542A3 Compounds and methods for treatment and diagnosis of mycobacterial infections |
| 07/09/1998 | DE3590035C2 Synergistic analgesic and antiinflammatory compsn. |
| 07/09/1998 | CA2650204A1 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 07/09/1998 | CA2605707A1 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 07/09/1998 | CA2278031A1 G-rich oligo aptamers and methods of modulating an immune response |
| 07/09/1998 | CA2276745A1 Mycobacterium fol a gene that encodes for the enzyme dihydrofolate reductase |
| 07/09/1998 | CA2276610A1 3-aryl substituted pyrazolo¬4,3-d|pyrimidine derivatives; corticotropin-releasing factor receptor (crf1) specific ligands |
| 07/09/1998 | CA2276465A1 Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations |
| 07/09/1998 | CA2276398A1 Selective inhibitors of prostaglandin endoperoxide synthase-2 |
| 07/09/1998 | CA2276394A1 Poly(diallylamine)-based bile acid sequestrants |
| 07/09/1998 | CA2276288A1 Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor |
| 07/09/1998 | CA2276184A1 Brain targeted low molecular weight hydrophobic antioxidant compounds |
| 07/09/1998 | CA2276150A1 Inhibitors of farnesyl-protein transferase |
| 07/09/1998 | CA2276081A1 Inhibitors of farnesyl-protein transferase |
| 07/09/1998 | CA2275975A1 Human mage-like protein |
| 07/09/1998 | CA2275943A1 Farnesyl transferase inhibitors |
| 07/09/1998 | CA2275668A1 Sulfonamide compounds having 5-ht receptor activity |
| 07/09/1998 | CA2275604A1 Sustained release cisapride mini-tablet formulation |
| 07/09/1998 | CA2274909A1 Cyclic organoselenium compounds, their preparation and their uses |
| 07/09/1998 | CA2271885A1 Substituted benzo[1,4]dioxanes as antiobesity agents |
| 07/09/1998 | CA2247306A1 Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis |
| 07/09/1998 | CA2239781A1 N-linked ureas and carbamates of heterocyclic thioesters |
| 07/09/1998 | CA2194750A1 Methods of elevating amounts of hyaluronan in the human body |
| 07/08/1998 | EP0852236A1 Anti-inflammatory agent |
| 07/08/1998 | EP0852231A2 16-Membered macrolide derivative having sustained antibacterial activity in plasma, synthesis intermediate thereof and process for producing the same |
| 07/08/1998 | EP0852226A1 Pyrimidine derivatives |
| 07/08/1998 | EP0852225A1 Fibrinogen receptor antagonists and medicinal preparations containing the same as the active ingredient |
| 07/08/1998 | EP0852143A1 Stable vitamin c preparation |
| 07/08/1998 | EP0852142A1 Diamines in the treatment of arrhythmia |
| 07/08/1998 | EP0852141A1 Nifedipine containing pharmaceutical extended release composition and a process for the preparation thereof |
| 07/08/1998 | EP0852117A1 Lipid metabolism ameliorants |
| 07/08/1998 | EP0851935A2 Dna construct comprising a muscle specific regulatory element for immunization or gene therapy |
| 07/08/1998 | EP0851929A1 CYTIDINE DEAMINASE cDNA AS A POSITIVE SELECTABLE MARKER FOR GENE TRANSFER, GENE THERAPY AND PROTEIN SYNTHESIS |
| 07/08/1998 | EP0851927A2 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 07/08/1998 | EP0851925A1 Human growth hormone variants |
| 07/08/1998 | EP0851923A2 Fmr1-related protein |
| 07/08/1998 | EP0851921A1 Genetic alterations related to familial alzheimer's disease |
| 07/08/1998 | EP0851876A1 Antisecretory factor peptides regulating pathological permeability changes |
| 07/08/1998 | EP0851873A2 Parainfluenza virus glycoproteins and vaccines |
| 07/08/1998 | EP0851871A1 Inhibition of tumor growth |
| 07/08/1998 | EP0851866A1 Therapeutic compounds |
| 07/08/1998 | EP0851865A1 Novel heterocyclic compounds |
| 07/08/1998 | EP0851862A1 1(hetero)aryl-4-(condensed thiazol-2-ylalkyl)-piperazine derivatives, their preparation and their use in the treatment of 5-ht1a-receptor mediated disorders |
| 07/08/1998 | EP0851859A1 Pyridinium derivatives and pharmaceutical compositions containing them |
| 07/08/1998 | EP0851857A1 Inhibitors of tumor necrosis factor alpha |
| 07/08/1998 | EP0851856A1 Indole derivatives as melatoninergic analogues |
| 07/08/1998 | EP0851855A1 Acylated derivatives of melatonin and its analogues, useful as medicaments |
| 07/08/1998 | EP0851769A1 Gene therapy using ovine adenoviral vectors |
| 07/08/1998 | EP0851768A2 Interactive molecular conjugates |
| 07/08/1998 | EP0851765A1 Therapeutic and prophylactic methods using heat shock proteins |
| 07/08/1998 | EP0851763A1 Method and composition for enhanced parenteral nutrition |
| 07/08/1998 | EP0851762A1 Pharmaceutical combination preparations containing erythropoietin and iron preparations |
| 07/08/1998 | EP0851761A1 Anti-intoxication composition |
| 07/08/1998 | EP0851760A1 Interleukin converting enzyme and apoptosis |
| 07/08/1998 | EP0851759A1 Compounds and methods |